GlassScriptPhysician profile
Chris M Pries
NPI 1205897337
$802.34
in general payments reported to CMS, 2019-2025
18 companies · $170 in 2025
The $170 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.51 · 2022: $28.52 · 2023: $263 · 2024: $317 · 2025: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $749.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $146.19 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $141.63 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $109.79 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $67.96 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.61 | 2022-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $32.49 | 2023-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $29.87 | 2025 | Auvelity |
| Lundbeck LLC | $28.50 | 2022-2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $24.51 | 2021 | |
| Harmony Biosciences LLC | $22.53 | 2024 | |
| Corium, LLC | $20.67 | 2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $17.60 | 2024 | Cobenfy |
| Indivior INC. | $17.26 | 2023 | Perseris |
| Almatica Pharma LLC | $17.14 | 2024 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $16.48 | 2023 | Jornay Pm |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $16.32 | 2023 | Fanapt, Hetlioz |
| Merck Sharp & Dohme LLC | $14.11 | 2023 | Belsomra |
| Neurocrine Biosciences, INC. | $13.68 | 2024 | Ingrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Pries listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.